Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3/A

HALOZYME THERAPEUTICS INC

Form 3/A

February 11, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement HALOZYME THERAPEUTICS INC [HTI] Frost Gregory Ian (Month/Day/Year) 01/18/2005 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O HALOZYME 03/19/2004 (Check all applicable) THERAPEUTICS, INC.. 11588 SORRENTO 10% Owner _X_ Director VALLEY ROAD, SUITE 17 _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group VP and Chief Scientific Off. Filing(Check Applicable Line) _X_ Form filed by One Reporting

SAN DIEGO, CAÂ 92121

(State)

(City)

Table I - Non-Derivative Securities Beneficially Owned

Person

Reporting Person

Form filed by More than One

2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect

(Instr. 5)

Common Stock 2,953,779

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

SEC 1473 (7-02)

D

Â

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

2. Date Exercisable and 3. Title and Amount of 6. Nature of 1. Title of Derivative 5. Ownership Indirect Beneficial Security **Expiration Date** Securities Underlying Conversion (Month/Day/Year) (Instr. 4) Derivative Security or Exercise Form of Ownership

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 3/A

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Options to Purchase Common Stock	11/11/2003(1)	11/11/2013	Common Stock	1,235,601	\$ 0.43	D	Â
Warrants to Purchase Common Stock (2003 Bridge Financing)	10/20/2003	10/20/2007	Common Stock	22,241	\$ 0.4496	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
Frost Gregory Ian C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY ROAD, SUITE 17 SAN DIEGO, CA 92121	ÂX	Â	VP and Chief Scientific Off.	Â		

Signatures

/s/ Gregory Frost 02/08/2005

**Signature of Person

Date

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 230,153 shares vest on 11/11/2003, 78,748 shares vests on 5/3/2004, 6,563 shares vests on 6/1/2004 and 25,743 shares vest on the 1st day of each month until option is fully vested, contingent upon continued employment with the Company

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2